As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Rani Therapeutics Holdings, Inc. The largest reported stake is InCube Labs, L.L.C.'s, at 22.1%. 18 filings are on record since July 17, 2025 (Schedule 13D/A, October 27, 2025).
Who owns Rani Therapeutics Holdings, Inc.?
Sell to companies like Rani Therapeutics Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 11,530,414 · Sole dispositive: 0 · Shared dispositive: 11,530,414 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Vanguard Capital Management · Sole voting: 489,877 · Shared voting: 0 · Sole dispositive: 5,052,862 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-31
- · Holder: Samsara BioCapital, L.P. · Percent: 9.9% · SCHEDULE 13D/A
- · Holder: SymBiosis Capital Partners, LLC · Percent: 4.4% · SCHEDULE 13G/A
- · Holder: Vanguard Capital Management · Percent: 5.12% · SCHEDULE 13G
Rani Therapeutics Holdings, Inc. has 18 Schedule 13D or 13G filings on record since 2025-07-17. 5 holders' latest filing reports 5% or more of class a common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| InCube Labs, L.L.C. | 22.1% | 22,424,788 | SCHEDULE 13D/A, 2025-10-27 | 2025-10-23 |
| 9.99% | 9,825,911 | SCHEDULE 13G, 2025-10-23 | 2025-10-16 | |
| RA Capital Management, L.P. | 9.9% | 11,530,414 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Samsara BioCapital, L.P. | 9.9% | 5,661,481 | SCHEDULE 13D/A, 2026-05-28 | 2026-05-26 |
| AWM Investment Company, Inc. | 9.9% | 9,745,343 | SCHEDULE 13G, 2026-02-13 | 2025-12-31 |
| Armistice Capital, LLC | 4.99% | 2,515,652 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| South Cone Investments Limited Partnership | 4.9% | 2,379,194 | SCHEDULE 13D/A, 2025-10-22 | 2025-10-20 |
| Vanguard Capital Management | 4.49% | 5,052,862 | SCHEDULE 13G/A, 2026-07-31 | 2026-06-30 |
| SymBiosis Capital Partners, LLC | 4.4% | 4,433,620 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-27 |
| Orca Capital AG | 4.3% | 1,891,623 | SCHEDULE 13G/A, 2025-07-23 | 2025-07-22 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Rani Therapeutics Holdings, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Rani Therapeutics Holdings, Inc. and the records around it.
Rani Therapeutics Holdings, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Form D filing Nov 2025
- Who owns it
Companies that share a holder
- SymBiosis Capital Partners, LLC also filed stake reports on 1 other company: Generation Bio Co. (Nov 2025)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), KALARIS THERAPEUTICS, INC. (May 2026)
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
Watch Rani Therapeutics Holdings, Inc.
Get an email when Rani Therapeutics Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Rani Therapeutics Holdings, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Rani Therapeutics Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rani Therapeutics Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
22 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | 0 | 11,530,414 | 0 | 11,530,414 | SCHEDULE 13G/A, 2026-08-14 |
| Peter Kolchinsky | 0 | 11,530,414 | 0 | 11,530,414 | SCHEDULE 13G/A, 2026-08-14 |
| Rajeev Shah | 0 | 11,530,414 | 0 | 11,530,414 | SCHEDULE 13G/A, 2026-08-14 |
| RA Capital Healthcare Fund, L.P. | 0 | 11,530,414 | 0 | 11,530,414 | SCHEDULE 13G/A, 2026-08-14 |
| Vanguard Capital Management | 489,877 | 0 | 5,052,862 | 0 | SCHEDULE 13G/A, 2026-07-31 |
The latest filing identifies Rani Therapeutics Holdings, Inc. by CUSIP 753018100 and gives its principal executive office as 2051 RINGWOOD AVENUE, SAN JOSE, CA 95131 (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
Due to the Beneficial Ownership Blocker listed in the Warrants, each Reporting Person's beneficial ownership percentage was 9.99% as of June 30, 2026.RA Capital Management, L.P., SCHEDULE 13G/A, 2026-08-14
Purpose of Transaction (Item 4)
South Cone Investments Limited Partnership
Item 4 of the Schedule 13D is hereby amended and restated by the following: The Reporting Persons acquired and hold the shares of Class A Common Stock reported herein for investment purposes. The Reporting Persons intend to review their investment on a regular basis and, as a result thereof, may at any time or from time to time determine to, directly or indirectly (a) acquire additional securities of the Issuer, through open market purchases, privately negotiated transactions or otherwise, (b) dispose of all or a portion of the securities of the Issuer owned by it in the open market, in privately negotiated transactions or otherwise, (c) enter into privately negotiated derivative transactions with institutional counterparties to hedge the market risk of some or all of its positions in the securities of the Issuer or (d) take any other available course of action, which could involve one or more of the types of transactions or have one or more of the results described in clauses (a) through (j) of Item 4 of Schedule 13D. Any such acquisition or disposition or other transaction would be made in compliance with all applicable laws and regulations. Notwithstanding anything contained herein, the Reporting Persons specifically reserve the right to change their intention with respect to any or all of such matters. In reaching any decision as to its course of action (as well as to the specific elements thereof), the Reporting Persons currently expect that it would take into …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-10-22; the filing has the rest
InCube Labs, L.L.C.
The information set forth in Item 1 and Item 3 of this Amendment No. 1 is incorporate herein by reference. Item 4 of the Statement is hereby amended and supplemented as follows: In connection with a private placement, as promptly as possible following the closing, but in no event later than ninety (90) days following the closing date, the Issuer has agreed to use reasonable best efforts to: (a) amend the Issuer's Amended and Restated Certificate of Incorporation to, among other things, effect the following: (i) reduce the number of votes to which each share of Class B Common Stock is entitled from ten (10) votes to one (1) vote, (ii) eliminate the ability of the Issuer's stockholders to act by written consent, and (iii) include additional stockholder protective provisions (not including a classified board) (which provisions shall be reasonably acceptable to Samsara BioCapital, an unrelated investor in the private placement, (b) make necessary conforming changes to the Issuer's Amended and Restated Bylaws as a result of the amendments contemplated by (a) above, (c) make necessary conforming changes to that certain Fifth Amended and Restated Limited Liability Company Agreement of Rani Therapeutics, LLC, dated August 3, 2021, as a result of the amendments contemplated by (a) above, and (d) terminate that certain Tax Receivable Agreement, dated August 3, 2021. The form of Securities Purchase Agreement is filed as Exhibit 99.1 hereto. The foregoing description is qualified in …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-10-27; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | Orca Capital AG | 9.9% | SCHEDULE 13G |
| 2025-07-23 | Orca Capital AG | 4.3% | SCHEDULE 13G/A |
| 2025-08-14 | Armistice Capital, LLC | 8.79% | SCHEDULE 13G |
| 2025-10-22 | South Cone Investments Limited Partnership | 4.9% | SCHEDULE 13D/A |
| 2025-10-23 | Raymond Debbane | 9.99% | SCHEDULE 13G |
| 2025-10-27 | InCube Labs, L.L.C. | 22.1% | SCHEDULE 13D/A |
| 2025-10-30 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G |
| 2025-10-30 | Samsara BioCapital, L.P. | 9.9% | SCHEDULE 13D |
| 2025-11-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-01-30 | The Vanguard Group | 5.23% | SCHEDULE 13G |
| 2026-02-12 | SymBiosis Capital Partners, LLC | 6.5% | SCHEDULE 13G |
| 2026-02-13 | AWM Investment Company, Inc. | 9.9% | SCHEDULE 13G |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-30 | Vanguard Capital Management | 5.12% | SCHEDULE 13G |
| 2026-05-15 | SymBiosis Capital Partners, LLC | 4.4% | SCHEDULE 13G/A |
| 2026-05-28 | Samsara BioCapital, L.P. | 9.9% | SCHEDULE 13D/A |
| 2026-07-31 | Vanguard Capital Management | 4.49% | SCHEDULE 13G/A |
| 2026-08-14 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
Questions about who owns Rani Therapeutics Holdings, Inc.
Who owns Rani Therapeutics Holdings, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Rani Therapeutics Holdings, Inc.: InCube Labs, L.L.C. (22.1%, Schedule 13D/A, filed 2025-10-27), Raymond Debbane (9.99%, Schedule 13G, filed 2025-10-23), RA Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-08-14), Samsara BioCapital, L.P. (9.9%, Schedule 13D/A, filed 2026-05-28) and AWM Investment Company, Inc. (9.9%, Schedule 13G, filed 2026-02-13).
Who are the largest shareholders of Rani Therapeutics Holdings, Inc.?
By the share each holder's latest filing reports, the largest holders of Rani Therapeutics Holdings, Inc. on this page are InCube Labs, L.L.C. (22.1%), Raymond Debbane (9.99%) and RA Capital Management, L.P. (9.9%).
When did InCube Labs, L.L.C. buy into Rani Therapeutics Holdings, Inc.?
The filings give report dates, not purchase dates. The earliest filing from InCube Labs, L.L.C. on this page is the Schedule 13D/A, filed 2025-10-27, reporting 22.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 18 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Rani Therapeutics Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 4, 2026 | Leadership change: Michelle Gilson appointed | — | Leadership changes | Source |
| June 30, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| May 15, 2026 | Leadership change: Svai Sanford departs, Chief Financial Officer | — | Leadership changes | Source |
| November 10, 2025 | Form D, private offering | $60.26M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Rani Therapeutics Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.